Drugs / RSM-932A CATION
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01215864 | Jan 2011 → Feb 2014 | cancer | Traslational Cancer Drugs Pharma, SL | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSM-932A CATION | ChEMBL registry synonym — accepted as the source's own label CHEMBL1181829 ↗ |
| Known as | RSM 932A | ChEMBL registry synonym — accepted as the source's own label CHEMBL1181829 ↗ |
| Known as | TCD-717 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01215864 ↗ |
| Action | Inhibit | “a specific inhibitor of the enzyme choline kinase alpha” NCT01215864 ↗1“Choline kinase alpha inhibitor” CHEMBL1181829 ↗ |
| Modality | Small molecule | — CHEMBL1181829 ↗ |
| Route | Intravenous | “TCD-717 will be administered as a 4 hour infusion” NCT01215864 ↗ |
| Target | CHKA | “Choline kinase alpha inhibitor” CHEMBL1181829 ↗ |